Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors

Jennifer Choi; Ronald Anderson; Ada Blidner; Tim Cooksley; Michael Dougan; Ilya Glezerman; Pamela Ginex; Monica Girotra; Dipti Gupta; Douglas Johnson; Vickie R. Shannon; Maria Suarez-Almazor; Bernardo L. Rapoport; Mario E. Lacouture

doi:10.1007/s00520-020-05706-4

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors

Jennifer Choi, Ronald Anderson, Ada Blidner, Tim Cooksley, Michael Dougan, Ilya Glezerman, Pamela Ginex, Monica Girotra, Dipti Gupta, Douglas Johnson, Vickie R. Shannon, Maria Suarez-Almazor, Bernardo L. Rapoport, Mario E. Lacouture

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.

Original language	English (US)
Pages (from-to)	6119-6128
Number of pages	10
Journal	Supportive Care in Cancer
Volume	28
Issue number	12
DOIs	https://doi.org/10.1007/s00520-020-05706-4
State	Published - Dec 2020

Keywords

Bullous dermatoses
Corticosteroids
Cutaneous IrAEs
Inflammatory dermatitis
Pruritus
Skin rash
Vitiligo

ASJC Scopus subject areas

Oncology

Access to Document

10.1007/s00520-020-05706-4

Cite this

Choi, J., Anderson, R., Blidner, A., Cooksley, T., Dougan, M., Glezerman, I., Ginex, P., Girotra, M., Gupta, D., Johnson, D., Shannon, V. R., Suarez-Almazor, M., Rapoport, B. L., & Lacouture, M. E. (2020). Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Supportive Care in Cancer, 28(12), 6119-6128. https://doi.org/10.1007/s00520-020-05706-4

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. / Choi, Jennifer; Anderson, Ronald; Blidner, Ada et al.
In: Supportive Care in Cancer, Vol. 28, No. 12, 12.2020, p. 6119-6128.

Research output: Contribution to journal › Article › peer-review

Choi, J, Anderson, R, Blidner, A, Cooksley, T, Dougan, M, Glezerman, I, Ginex, P, Girotra, M, Gupta, D, Johnson, D, Shannon, VR , Suarez-Almazor, M, Rapoport, BL & Lacouture, ME 2020, 'Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors', Supportive Care in Cancer, vol. 28, no. 12, pp. 6119-6128. https://doi.org/10.1007/s00520-020-05706-4

@article{cba0a21cb5a344629ce25c09a0b0815a,

title = "Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors",

abstract = "Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.",

keywords = "Bullous dermatoses, Corticosteroids, Cutaneous IrAEs, Inflammatory dermatitis, Pruritus, Skin rash, Vitiligo",

author = "Jennifer Choi and Ronald Anderson and Ada Blidner and Tim Cooksley and Michael Dougan and Ilya Glezerman and Pamela Ginex and Monica Girotra and Dipti Gupta and Douglas Johnson and Shannon, {Vickie R.} and Maria Suarez-Almazor and Rapoport, {Bernardo L.} and Lacouture, {Mario E.}",

note = "Publisher Copyright: {\textcopyright} 2020, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2020",

month = dec,

doi = "10.1007/s00520-020-05706-4",

language = "English (US)",

volume = "28",

pages = "6119--6128",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer Verlag",

number = "12",

}

TY - JOUR

T1 - Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors

AU - Choi, Jennifer

AU - Anderson, Ronald

AU - Blidner, Ada

AU - Cooksley, Tim

AU - Dougan, Michael

AU - Glezerman, Ilya

AU - Ginex, Pamela

AU - Girotra, Monica

AU - Gupta, Dipti

AU - Johnson, Douglas

AU - Shannon, Vickie R.

AU - Suarez-Almazor, Maria

AU - Rapoport, Bernardo L.

AU - Lacouture, Mario E.

PY - 2020/12

Y1 - 2020/12

N2 - Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.

AB - Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.

KW - Bullous dermatoses

KW - Corticosteroids

KW - Cutaneous IrAEs

KW - Inflammatory dermatitis

KW - Pruritus

KW - Skin rash

KW - Vitiligo

UR - http://www.scopus.com/inward/record.url?scp=85089910876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089910876&partnerID=8YFLogxK

U2 - 10.1007/s00520-020-05706-4

DO - 10.1007/s00520-020-05706-4

M3 - Article

C2 - 32856211

AN - SCOPUS:85089910876

SN - 0941-4355

VL - 28

SP - 6119

EP - 6128

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - 12

ER -

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this